Table 4.
ADMET | Property/ Parameter |
MP-001-739-296 | MP-005-944-636 | MP-005-945-924 | MP-035-706-028 | MP-039-052-338 | N3 | α-ketoamide |
---|---|---|---|---|---|---|---|---|
Absorption | Water solubility (log mol/L) |
−3.52 | −4.74 | −2.00 | −3.39 | −3.29 | −3.85 | −3.84 |
Caco2 permeability (log Papp, 10-6 cm/s) |
0.66 | 0.54 | 0.50 | −0.19 | −0.35 | 0.56 | 0.38 | |
Intestinal absorption (% Absorbed) |
49.15 | 85.64 | 46.12 | 58.25 | 68.87 | 53.99 | 65.54 | |
Skin Permeability (log Kp) |
−2.73 | −2.87 | −2.89 | −2.74 | −2.74 | −2.74 | −2.75 | |
P-glycoprotein sub | No | Yes | No | Yes | Yes | Yes | Yes | |
P-glycoprotein I inh | No | Yes | No | No | No | Yes | Yes | |
P-glycoprotein II inh | No | Yes | No | No | Yes | No | Yes | |
Distribution | VD (human) (log L/kg) |
−0.84 | 0.19 | −0.21 | −0.22 | 0.56 | −0.49 | 0.09 |
Fraction unbound (human) (Fu) |
0.20 | 0.22 | 0.50 | 0.17 | 0.09 | 0.19 | 0.05 | |
BBB permeability (log BB) |
−0.54 | −1.07 | −0.99 | −1.29 | −1.18 | −1.41 | −1.07 | |
CNS permeability (log PS) |
−2.98 | −2.84 | −3.57 | −3.72 | −3.19 | −3.97 | −3.52 | |
Metabolism | CYP2D6 sub | No | No | No | No | No | No | No |
CYP3A4 sub | Yes | Yes | No | Yes | Yes | Yes | Yes | |
CYP1A2 inh | No | No | No | No | Yes | No | No | |
CYP2C19 inh | No | Yes | No | No | No | No | No | |
CYP2C9 inh | No | No | No | No | Yes | No | No | |
CYP2D6 inh | No | No | No | No | No | No | No | |
CYP3A4 inh | No | Yes | No | No | Yes | Yes | Yes | |
Excretion | Total Clearance (log ml/min/kg) |
1.24 | 1.32 | 0.20 | 0.12 | 0.47 | 0.44 | 0.16 |
Renal OCT2 sub | No | No | No | No | No | No | No | |
Organ Toxicity to human | Hepatotoxicity# | 0.81 | 0.8 | 0.84 | 0.88 | 0.73 | 0.64 | 0.66 |
Carcinogenicity# | 0.5 | 0.72 | 0.85 | 0.8 | 0.66 | 0.52 | 0.6 | |
Mutagenicity# | 0.85 | 0.9 | 0.77 | 0.72 | 0.51 | 0.59 | 0.63 | |
Cytotoxicity# | 0.61 | 0.78 | 0.78 | 0.79 | 0.86 | 0.69 | 0.51 | |
AMES toxicity | No | No | Yes | No | No | No | No | |
hERG I inhibitor | No | No | No | No | No | No | No | |
hERG II inhibitor | No | No | No | No | Yes | Yes | Yes | |
Oral Rat AT (LD50) (mol/kg) |
2.08 | 2.23 | 1.97 | 2.54 | 2.53 | 3.538 | 2.155 | |
Oral Rat CT (LOAEL) (log mg/kg_bw/day) |
0.68 | 1.994 | 3.489 | 3.154 | 2.418 | 3.417 | 2.142 | |
Skin Sensitization | No | Yes | No | No | No | No | No | |
Tox21-Nuclear receptor signaling pathways |
AhR# | 0.98 | 0.89 | 0.85 | 0.8 | 0.83 | 0.91 | 0.91 |
AR# | 0.93 | 0.98 | 0.96 | 0.95 | 0.92 | 0.95 | 0.97 | |
AR-LBD# | 0.94 | 1 | 0.97 | 0.97 | 0.94 | 0.97 | 0.98 | |
Aromatase# | 0.85 | 0.97 | 0.96 | 0.81 | 0.74 | 0.95 | 0.91 | |
ER-Alpha# | 0.85 | 0.58 | 0.82 | 0.71 | 0.6 | 0.88 | 0.87 | |
ER- LBD# | 0.92 | 0.59 | 0.96 | 0.92 | 0.84 | 0.92 | 0.96 | |
PPAR-Gamma# | 0.98 | 0.91 | 0.98 | 0.9 | 0.81 | 0.92 | 0.96 | |
Tox21-Stress response pathways | nrf2/ARE | 0.83 | 0.78 | 0.96 | 0.86 | 0.8 | 0.93 | 0.93 |
HSE | 0.83 | 0.78 | 0.96 | 0.86 | 0.8 | 0.93 | 0.93 | |
MMP | 0.67 | 0.51 | 0.92 | 0.7 | 0.64 | 0.88 | 0.69 | |
p53 | 0.91 | 0.82 | 0.9 | 0.72 | 0.69 | 0.88 | 0.83 | |
ATAD5 | 0.99 | 0.97 | 0.96 | 0.93 | 0.88 | 0.95 | 0.91 | |
Toxicity target* |
Receptor# | AR (75.1%) |
NF | PG/H S1 (94.3%) | GR (81.9%) |
AR (72.3%) | N/A | N/A |
Predicted Toxicity | LD50# mg/kg |
3000 | 2000 | 4000 | 1500 | 3919 | 4000 | 675 |
Toxicity Class | Class# | 4 | 4 | 5 | 4 | 5 | 5 | 4 |
Toxicity to environment | T. Pyriformis (log ug/L) |
0.39 | 1.10 | 0.29 | 0.29 | 0.36 | 0.285 | 0.291 |
Minnow toxicity (log mM) |
1.04 | −0.49 | 3.80 | 3.20 | 3.57 | 5.647 | 2.122 | |
Strong Active | Strong Inactive | Weak Active | Weak Inactive |